BP1003降低了STAT3表达及其在固体瘤和瘤微环境中的前瘤功能
Maria Gagliardi1, Rhonda Kean2, Bingbing Dai3,4
1Bio-Path Holdings Inc., Bellaire, TX 77401, USA.
Biomedicines
|August 29, 2024
概括
BP1003是一种反感性寡度氧核酸 (ASO),准STAT3,以克服癌症药物耐药性和免疫逃避. 这种新疗法在乳腺,卵巢和胰腺癌的临床前模型中显示出广泛的抗瘤作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 信号传感器和转录3 (STAT3) 激活器的失调驱动癌症的发展,耐药性和免疫逃避.
- 向STAT3为新型癌症疗法提供了一个有前途的战略.
研究的目的:
- 为了评估BP1003的疗效,一个针对STAT3的反感性寡氧核酸 (ASO),作为癌症治疗药物.
- 评估BP1003对癌细胞对化疗敏感性的影响及其对瘤微环境的影响.
主要方法:
- BP1003是一种包装在中性脂质体中的P-乙氧ASO,旨在增强稳定性和细胞吸收.
- 在HER2+,三阴性乳腺癌,晚期卵巢癌和患者衍生的胰腺管腺癌 (PDAC) 模型中测试了疗效.
- 对STAT3表达,化疗敏感性 (paclitaxel,5-FU,gemcitabine) 和免疫细胞分化 (巨细胞) 的影响在2D,3D,ex vivo和in vivo模型中进行了分析.
主要成果:
- 在乳腺和卵巢癌细胞中,BP1003显著降低了STAT3表达,并增强了化疗敏感性.
- 在PDAC模型中,使用BP1003和gemcitabine的联合治疗降低了组织活力和瘤体积.
- BP1003抑制了单细胞分化成抗炎M2巨细胞,表明了免疫调节的潜力.
结论:
- 通过抑制STAT3.3,BP1003在各种固体瘤模型中表现出广泛的抗瘤活性.
- BP1003增强化疗效率,调节瘤微环境,将其定位为癌症免疫治疗的有希望的候选人.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


